“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Seasonal shifts are driving unusual surges in respiratory illnesses in 2025, with COVID-19, influenza, and RSV showing new ...

COVID-19 activity is rising in much of the country. Data shows overall respiratory virus spread is very low in the U.S.

The Centers for Disease Control and Prevention and the Department of Health and Human Services adopted Aug. 4 the Advisory Committee on Immunization Practices’ recommendations for respiratory ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Pregnant individuals commonly reported hesitancy toward RSVpreF and nirsevimab, indicating the need for efforts to promote the safety and uptake of RSV immunization.

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory ...

RSV-Related Hospitalizations and Comorbidities: Two Surprises Here —A recent study examined several broad categories of comorbidities in an attempt to determine which ones correlated with ...

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in infants younger than 6 months globally. A maternal bivalent RSV prefusion F (RSVpreF) vaccine was ...

Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, research suggests.

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.